TY  - JOUR
AU  - Kind, Felix
AU  - Eder, Ann-Christin
AU  - Jilg, Cordula A
AU  - Hartrampf, Philipp E
AU  - Meyer, Philipp T
AU  - Ruf, Juri
AU  - Michalski, Kerstin
TI  - Prognostic Value of Tumor Volume Assessment on PSMA PET After 177Lu-PSMA Radioligand Therapy Evaluated by PSMA PET/CT Consensus Statement and RECIP 1.0.
JO  - Journal of nuclear medicine
VL  - 64
IS  - 4
SN  - 0097-9058
CY  - New York, NY
PB  - Soc.
M1  - DKFZ-2023-00701
SP  - 605 - 610
PY  - 2023
AB  - Quantitative evaluation of prostate-specific membrane antigen (PSMA)-targeting PET/CT remains challenging but is urgently needed for the use of standardized PET-based response criteria, such as the PSMA PET/CT consensus statement or Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0). A recent study evaluated the prognostic value of whole-body tumor volume using a semiautomatic method relying on a 50
KW  - Male
KW  - Humans
KW  - Prognosis
KW  - Positron Emission Tomography Computed Tomography: methods
KW  - Retrospective Studies
KW  - Treatment Outcome
KW  - Prostate-Specific Antigen
KW  - Tumor Burden
KW  - Prostatic Neoplasms, Castration-Resistant: diagnostic imaging
KW  - Prostatic Neoplasms, Castration-Resistant: radiotherapy
KW  - Dipeptides: adverse effects
KW  - Heterocyclic Compounds, 1-Ring: adverse effects
KW  - Lutetium
KW  - PSMA PET/CT (Other)
KW  - PSMATV50 (Other)
KW  - RECIP 1.0 (Other)
KW  - radioligand therapy (Other)
KW  - response assessment (Other)
KW  - gallium 68 PSMA-11 (NLM Chemicals)
KW  - Prostate-Specific Antigen (NLM Chemicals)
KW  - Dipeptides (NLM Chemicals)
KW  - Heterocyclic Compounds, 1-Ring (NLM Chemicals)
KW  - Lutetium (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:36302658
DO  - DOI:10.2967/jnumed.122.264489
UR  - https://inrepo02.dkfz.de/record/275254
ER  -